¹Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Congo
²Department of Rheumatology, Brazzaville University Hospital Center, Brazzaville, Congo

*Corresponding Author: Affleck Romaric Ledier Angalla, Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Congo.

Received: January 17, 2021; Published: May 14, 2021

Abstract

Goal: Improve the management of osteonecrosis in sickle cell patients.

Materials and Methods: Retrospective study, conducted from January 1, 2001 to June 30, 2010, i.e. 9 years and 6 months in the departments of Rheumatology, Clinical Hematology, Orthopedic Traumatology, Childhood Surgery and Pediatrics Grand Children of the University Hospital of Brazzaville-Congo. The diagnosis of sickle cell osteonecrosis was made based on anamnestic, clinical and paraclinical arguments (radiological classification by Arlet and Ficat).

Results: We included 31 cases of sickle cell osteonecrosis (0.6%), including 18 female (58.1%) and 13 male (41.9%), with a sex ratio of 0.72 (M/F). The mean age was 25.6 years (range 10 and 44). The hip was the seat of the most common osteonecrosis: left unilateral in 15 cases (48.4%), right unilateral in 12 cases (38.7%) and bilateral in 4 cases (12.9%), follow-up of the shoulder, the location of which was bilateral in 2 cases (6.4%). According to the Arlet and Ficat classification, osteonecrosis was stage III in 15 patients (47.4%), stage II in 14 patients (45.1%) and stage IV in 2 cases (6.4%). The treatment combined medical treatment in all patients and surgical treatment in 6 patients (19.3%).

Conclusion: This work underlines that osteonecrosis is a serious and disabling complication of sickle cell anemia. Adequate management involves analgesics and NSAIDs in our context.

Keywords: Osteonecrosis; Sickle Cell Disease; Hemoglobinopathy S

References

1. Cook GC and Zumlai AI. “Tropical diseases”. Eds MANSON, 2003, 21^st Edition, London WL Saunders (2003): 1-5.
2. Bardakjian J and Wajcman H. “Epidemiology of sickle cell anemia”. Revue du Praticien 54 (2004): 1531-1533.
3. Serjeant GR. “Mortality from sickle cell disease in Africa”. British Medical Journal 330 (2005): 432-433.
4. “Acute complications of sickle cell anemia”. Revised Prat 54 (2004): 1548-1557.
5. Carayon A., et al. “Osteonecrosis manifestations of sickle cell disease”. Annals of Internal Medicine 122 (1971): 419-426.
6. Coulibaly Y., et al. “Aseptic osteonecrosis of the femoral head in sickle cell patients: epidemiological and therapeutic aspects in the department of orthopedic and trauma surgery”. Mali Medical 4 (2009): 43-46.
7. K N'Dri., et al. “Radiological and computed tomography aspects of the femoral head in sickle cell patients”. Francophone Health Studies and Research Papers 1 (2000): 27-30.
8. Homawoo K., et al. “Sickle cell anemia and osteonecrosis of the femoral head: therapeutic considerations in 38 cases”. Médecine d'Afrique Noire 38 (1991): 518-517.
9. Hernigou Ph. “Osteonecrosis of the femoral head before the prosthesis stage157 (2006): 4.
10. Elira Dokekias A and Nzingoula S. “Profile of homozygous sickle cell subject after 30 years”. Médecine d'Afrique Noire 10 (2001): 412-418.
11. Goudote E., et al. “Osteonecrosis, sickle cell disease of the hip in the People's Republic of Benin, concerning 22 observations”. Chir Afr Noire 1 (1981): 53-620.
12. Lafforque P. “Osteonecrosis of the femoral head”. Rev Rum 76 (2009): 166-172.
13. Akakpo-Numado GK., et al. “Aseptic osteonecrosis of the femoral head in children with sickle cell disease”. Francophone Health Studies and Research Notebooks4 (2008): 231-233.
14. Hernigou P. “Non-traumatic osteonecrosis of the epiphyses of adults; EMC (Elsevier Masson SAS, Paris), Musculoskeletal System, 14-028-A10 (2006).

Citation

Citation: Affleck Romaric Ledier Angalla., et al. “Sickle Cell Osteonecrosis, Report of 31 Cases in Congo Brazzaville”.Acta Scientific Medical Sciences 5.6 (2021): 59-63.

Copyright

Copyright: © 2021 Affleck Romaric Ledier Angalla., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.